Aimei Health Technology II is a SPAC incorporated in the Cayman Islands with no operations, no revenue, and no identified acquisition target. The company raised $60M (up to $69M with overallotment) through an IPO of units priced at $10.00, with proceeds held in a trust account invested in short-term U.S. government securities. Aimei Health II has 12 months from IPO close to complete a business combination, or it must redeem public shares at roughly $10.00 per share and liquidate. Management's stated focus is healthcare — specifically small-cap biopharmaceuticals, medical devices, and diagnostics — across North America, Europe, and Asia-Pacific, though no industry or geographic restrictions formally apply. The sponsor, Aimei Investment II Ltd, is wholly owned by a PRC citizen and acquired founder shares for roughly $25,000 total, creating highly asymmetric economics: the sponsor captures substantial value if any deal closes, but loses everything if no deal closes. Public shareholders have downside protection through the trust but face material dilution of roughly 34% at deal close, even without redemptions, due to founder share conversion, representative shares, and rights conversion. The company's strong China ties — the sponsor's owner is a PRC citizen and the sole executive is Hong Kong-based — may steer deal sourcing toward PRC targets and create CFIUS complications for U.S.-based acquisitions. The predecessor SPAC, Aimei Health Technology, completed a $69M IPO in December 2023 and has yet to close its pending business combination with United Hydrogen Group.